Characterization of Obesity in Severe Asthma in the German Asthma Net.


Journal

The journal of allergy and clinical immunology. In practice
ISSN: 2213-2201
Titre abrégé: J Allergy Clin Immunol Pract
Pays: United States
ID NLM: 101597220

Informations de publication

Date de publication:
11 2023
Historique:
received: 20 10 2022
revised: 17 06 2023
accepted: 20 06 2023
medline: 13 11 2023
pubmed: 6 7 2023
entrez: 5 7 2023
Statut: ppublish

Résumé

Asthma is increasingly recognized as heterogeneous, characterized by different endotypes, with obesity not only a distinct phenotype but a risk factor for severe asthma. We sought to understand the associations of obesity with relevant parameters of severe asthma, including asthma control, disease burden, and lung function. The German Asthma Net registry is a multicenter international real-life registry capturing long-term follow-up data. This analysis included 2213 patients (52 ± 16 years, 58% female, 29% with obesity [body mass index ≥30 kg/m Patients with obesity were more frequently female, more likely to have depression and gastroesophageal reflux, and suffered from worse asthma control, lower quality of life, reduced static lung volumes, more pronounced hypoxemia, and higher blood neutrophil counts, all statistically significant. Blood eosinophils, exhaled nitric oxide, and total IgE were independent of obesity. In the multiple regression analysis, obesity was significantly associated with more frequent reflux and depression, reduced static lung function values, older age, poor asthma control, and long-acting muscarinic antagonist therapy, and inversely associated with bronchiectasis and nonsmoking status. In this large, well-characterized cohort, we identified the association of obesity with a significantly higher disease burden and a similar portfolio of inflammation type 2 markers in patients with and without obesity; therefore, patients with obesity seem similarly eligible for the treatment with biologics targeting these disease endotypes.

Sections du résumé

BACKGROUND
Asthma is increasingly recognized as heterogeneous, characterized by different endotypes, with obesity not only a distinct phenotype but a risk factor for severe asthma.
OBJECTIVE
We sought to understand the associations of obesity with relevant parameters of severe asthma, including asthma control, disease burden, and lung function.
METHODS
The German Asthma Net registry is a multicenter international real-life registry capturing long-term follow-up data. This analysis included 2213 patients (52 ± 16 years, 58% female, 29% with obesity [body mass index ≥30 kg/m
RESULTS
Patients with obesity were more frequently female, more likely to have depression and gastroesophageal reflux, and suffered from worse asthma control, lower quality of life, reduced static lung volumes, more pronounced hypoxemia, and higher blood neutrophil counts, all statistically significant. Blood eosinophils, exhaled nitric oxide, and total IgE were independent of obesity. In the multiple regression analysis, obesity was significantly associated with more frequent reflux and depression, reduced static lung function values, older age, poor asthma control, and long-acting muscarinic antagonist therapy, and inversely associated with bronchiectasis and nonsmoking status.
CONCLUSION
In this large, well-characterized cohort, we identified the association of obesity with a significantly higher disease burden and a similar portfolio of inflammation type 2 markers in patients with and without obesity; therefore, patients with obesity seem similarly eligible for the treatment with biologics targeting these disease endotypes.

Identifiants

pubmed: 37406803
pii: S2213-2198(23)00714-6
doi: 10.1016/j.jaip.2023.06.049
pii:
doi:

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

3417-3424.e3

Informations de copyright

Copyright © 2023 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.

Auteurs

Christina Bal (C)

Department of Pneumology, University Hospital Vienna AKH, Medical University of Vienna, Vienna, Austria.

Wolfgang Pohl (W)

Karl Landsteiner Institute for Clinical and Experimental Pneumology, Vienna, Austria.

Katrin Milger (K)

Department of Medicine V, Ludwig-Maximilians-University (LMU) of Munich, Munich, Germany; Comprehensive Pneumology Center (CPC-M), German Center for Lung Research (DZL), Munich, Germany.

Dirk Skowasch (D)

Department of Internal Medicine II-Pneumology, University Hospital Bonn, Bonn, Germany.

Christian Schulz (C)

Department of Internal Medicine II, University Hospital Regensburg, Regensburg, Germany.

Monika Gappa (M)

Evangelisches Krankenhaus Düsseldorf, Children's Hospital, Düsseldorf, Germany.

Cordula Koerner-Rettberg (C)

Department of Pediatrics, Research Institute, Marien-Hospital Wesel, Wesel, Germany.

Margret Jandl (M)

Hamburger Institut für Therapieforschung GmbH, Hamburg, Germany.

Olaf Schmidt (O)

Pneumologische Gemeinschaftspraxis und Studienzentrum KPPK, Koblenz, Germany.

Sonja Zehetmayer (S)

Section for Medical Statistics, Center for Medical Statistics, Informatics, and Intelligent Systems, Medical University of Vienna, Vienna, Austria.

Christian Taube (C)

Department of Pulmonary Medicine, University Hospital Essen-Ruhrlandklinik, Essen, Germany.

Eckard Hamelmann (E)

Kinderzentrum Bethel, Evangelisches Klinikum Bethel, University Bielefeld, Bielefeld, Germany.

Roland Buhl (R)

Pulmonary Department, Mainz University Hospital, Mainz, Germany.

Stephanie Korn (S)

Department of Pneumology/Respiratory Medicine, Thoraxklinik Heidelberg, Heidelberg, Germany; IKF Pneumologie Mainz, Mainz, Germany. Electronic address: korn@ikf-pneumologie.de.

Marco Idzko (M)

Department of Pneumology, University Hospital Vienna AKH, Medical University of Vienna, Vienna, Austria.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH